Carl Zeiss Meditec's Q2 2024/25 Earnings Soar!

• Carl Zeiss Meditec AG reported approximately EUR 560 million in revenue for Q2 2024/25, a 19% increase from EUR 472.1 million in the previous year.
• The revenue growth includes EUR 54 million from the acquisition of Dutch Ophthalmic Research Center B.V. (DORC), contributing to the first-time consolidation since April 2024.
• Excluding the DORC contribution, the revenue growth would have been around 7%.
• EBITA for Q2 reached approximately EUR 78 million, up from EUR 67.2 million in the previous year, with earnings per share remaining stable at EUR 0.52.
• For the first half of 2024/25, total revenue was around EUR 1,050 million, with EBITA at EUR 114 million and earnings per share at EUR 0.70.
• The company anticipates moderate revenue growth and stable to slightly higher EBITA for the full fiscal year 2024/25, amid macro-economic uncertainties and potential trade tariffs.

The next important date, Publication of the semi-annual financial report, at Carl Zeiss Meditec is on 14.05.2025.

The price of Carl Zeiss Meditec at the time of the news was 56,15EUR and was down -0,80 % compared with the previous day.
15 minutes after the article was published, the price was 55,95EUR this corresponds to a minus of -0,36 % since publication.
At this time, the index MDAX was at 26.868,00PKT (+0,90 %).

Carl Zeiss Meditec

0,00 %

+5,36 %

-9,99 %

+5,59 %

-41,18 %

-50,87 %

-37,40 %

+155,85 %

+658,35 %

ISIN:DE0005313704WKN:531370

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max